New initiative takes Duracell beyond the battery
BETHEL, Conn. Duracell has launched its new Duracell Smart Power initiative, which expands the brand’s product portfolio beyond the traditional battery to address the ever-growing and ever-changing power needs of the modern consumer.
The company’s latest offerings, including the new drop-and-go myGrid charging pad, fall under an emerging category of personal power solutions and signify Duracell’s commitment to keeping today’s consumers connected to the devices they need the most at all times.
Duracell Smart Power and its range of personal power solutions continue the company’s focus on reliability, performance and technological innovation but now deliver added power efficiency allowing consumers the freedom to live beyond the grid. More than 10 new products mark the start of Duracell Smart Power ranging from myGrid to on-the-go compact power chargers, new rechargeable battery chargers and patented LED technology for flashlights.
“Duracell Smart Power is an evolution of Duracell’s heritage that builds upon the reliability and performance that our batteries have and will always deliver. This initiative will serve as an important lens for future product innovation as we expand the breadth of our offerings to address the evolution of personal power,” said Rick June, Duracell VP and general manager North America. “Our new personal power solutions allow consumers the freedom to live their lives without the limits of staying tethered to today’s power grid. It is charging made simple.”
Wild Child provides natural way to ‘Quit Nits’
LOS ANGELES Wild Child, an Australian-based natural healthcare products company showcased its Quit Nits head lice products at ECRM Health Care.
According to the company, from a survey of 1,002 parents of children ages 6 to 13, 69% of parents said it was extremely important that any lice solution they buy not contain any toxic chemicals. And 61% responded that the product should be safe for use by pregnant women. In addition, over 3-in-5 parents (64%) were bothered by the fact that many head lice treatments currently contain toxic ingredients with possible negative side effects.
Teva launches ‘Patient First’ project
WASHINGTON The world’s largest generic drug maker has started an initiative to tell stories of Americans who have difficulty paying for their prescription medications, and push for a regulatory approval pathway for biosimilars.
Teva Pharmaceuticals USA announced Thursday the “Patient First” project, part of its broader Year of Affordable Healthcare campaign.
One story is of Rob Day, who was diagnosed at age 19 with the rare blood disorder paroxysmal nocturnal hemoglobinuria, for which he must take an unspecified biotech drug that costs him $389,000 a year. Teva said a Food and Drug Administration approval pathway for biosimilars would help lower prices for drugs like the one Day takes.